Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 12098.145 | 0.8699 | 0.7340 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 12098.145 | 0.9694 | 0.9374 | 0.9769 | |
| SUM225CWN | HER2amp | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 12098.145 | 1.0009 | 1.0018 | 0.9769 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 0.000512 | uM | 11058.145 | 0.9741 | 0.9763 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 0.00256 | uM | 11058.145 | 1.0750 | 1.0667 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 0.0128 | uM | 11058.145 | 1.0219 | 1.0198 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 0.064 | uM | 11058.145 | 1.1517 | 1.1324 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 0.32 | uM | 11058.145 | 1.0598 | 1.0534 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 1.6 | uM | 11058.145 | 1.0544 | 1.0486 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 8 | uM | 11058.145 | 1.0143 | 1.0129 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 40 | uM | 11058.145 | 1.2293 | 1.1964 | 2.2039 | |
| SUM229PE | TNBC | - | Nilotinib | ABL | nRTK | 200 | uM | 11058.145 | 1.1413 | 1.1236 | 2.2039 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10695.145 | 1.0432 | 1.0759 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10695.145 | 0.9519 | 0.9151 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10695.145 | 0.9535 | 0.9179 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10695.145 | 1.0086 | 1.0151 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10695.145 | 1.0539 | 1.0946 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10695.145 | 0.9330 | 0.8815 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10695.145 | 0.8599 | 0.7511 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10695.145 | 0.8599 | 0.7512 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10695.145 | 0.4324 | -0.0440 | 1.1360 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 11852.145 | 0.9893 | 0.9862 | 1.5550 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 11852.145 | 0.9919 | 0.9896 | 1.5550 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 11852.145 | 1.0339 | 1.0433 | 1.5550 | |
| SUM52PE | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 11852.145 | 1.0321 | 1.0410 | 1.5550 |